Company profile for NeuroNOS

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Neuro-NOS is a pioneering biotech company specializing in next-generation neuroscience therapies, focusing on neurodegenerative diseases and neurological disorders. Leveraging cutting-edge research and innovative drug development, Neuro-NOS aims to deliver breakthrough treatments for conditions like Alzheimer’s, Parkinson’s, and ALS. With a strong foundation in molecular neuroscience and translational medicine, the company...
Neuro-NOS is a pioneering biotech company specializing in next-generation neuroscience therapies, focusing on neurodegenerative diseases and neurological disorders. Leveraging cutting-edge research and innovative drug development, Neuro-NOS aims to deliver breakthrough treatments for conditions like Alzheimer’s, Parkinson’s, and ALS. With a strong foundation in molecular neuroscience and translational medicine, the company is committed to accelerating novel therapies from lab to clinic. Neuro-NOS collaborates with leading researchers and institutions to push the boundaries of brain health innovation.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Boston, Massachusetts
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/02/13/3238036/0/en/Beyond-Air-Reports-Fiscal-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html

GLOBENEWSWIRE
13 Feb 2026
XTL Update On Recent Developments
XTL Update On Recent Developments

29 Jan 2026

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2026/01/29/3229091/0/en/XTL-Update-on-Recent-Developments.html

GLOBENEWSWIRE
29 Jan 2026

https://www.globenewswire.com/news-release/2026/01/13/3217669/0/en/XTL-Biopharmaceuticals-Acquires-85-of-Beyond-Air-s-Subsidiary-NeuroNOS-Entering-the-Massive-Autism-Market-with-Nobel-Prize-Winning-Scientific-Leadership.html

GLOBENEWSWIRE
13 Jan 2026

https://www.globenewswire.com/news-release/2025/09/08/3146057/0/en/NeuroNOS-Granted-FDA-Orphan-Drug-Designation-for-Glioblastoma-the-Most-Common-and-Deadliest-Primary-Malignant-Brain-Cancer-in-Adults.html

GLOBENEWSWIRE
08 Sep 2025

https://www.globenewswire.com/news-release/2025/04/21/3064971/0/en/NeuroNOS-Granted-FDA-Orphan-Drug-Designation-for-Phelan-McDermid-Syndrome-a-Neurodevelopmental-Disorder-Linked-to-Autism.html

GLOBENEWSWIRE
21 Apr 2025

https://www.globenewswire.com/news-release/2025/04/15/3062114/0/en/NeuroNOS-Appoints-Nobel-Prize-Laureate-Professor-Dan-Shechtman-to-Scientific-Advisory-Board.html

GLOBENEWSWIRE
15 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty